Stemline Therapeutics is developing three clinical candidates: ELZONRIST™ (tagraxofusp; SL-401), SL-801, and SL-701. ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123), was granted breakthrough therapy designation in blastic plasmacytoid dendritic cell neoplasm (BPDCN). A BLA is under review. Additional ELZONRIS clinical trials are ongoing in CMML and MF.
750 Lexington Ave, 11th floor
New York, New York 10022